Omitting Rituxan Dose Does Not Affect AAV Relapse Rates, Analysis Suggests
Omitting one dose of Rituxan (rituximab) in a previously tested, tailored treatment regimen did not impact the short-term relapse-free rate of people with ANCA-associated vasculitis (AAV), a post-hoc analysis of a Phase 3 trial showed.
The findings suggest this particular dose could be eliminated from the treatment protocol, according to the investigators. That would lower treatment-related toxicity and improve patients’ prognosis, while maintaining clinical remission.
However, these results do not imply causation as other factors may be at play, the researchers noted.
The analysis’ findings were reported in “Reducing the initial number of rituximab maintenance-therapy infusions for ANCA-associated vasculitides: randomized-trial post-hoc analysis,” published in the journal Rheumatology.